Bettina Hieronimus1, Valentina Medici2, Andrew A Bremer3, Vivien Lee4, Marinelle V Nunez5, Desiree M Sigala6, Nancy L Keim7, Peter J Havel6, Kimber L Stanhope4. 1. Max Rubner-Institut, Institute of Child Nutrition, Karlsruhe, Germany; Department of Molecular Biosciences, School of Veterinary Medicine, University of California, Davis, CA, United States of America. Electronic address: bettina.hieronimus@mri.bund.de. 2. Division of Gastroenterology and Hepatology, University of California, Davis, CA, United States of America. 3. Department of Pediatrics, School of Medicine, University of California, Davis, CA, United States of America; Pediatric Growth and Nutrition Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, United States of America. 4. Department of Molecular Biosciences, School of Veterinary Medicine, University of California, Davis, CA, United States of America. 5. Department of Nutrition, University of California, Davis, CA, United States of America. 6. Department of Molecular Biosciences, School of Veterinary Medicine, University of California, Davis, CA, United States of America; Department of Nutrition, University of California, Davis, CA, United States of America. 7. Department of Nutrition, University of California, Davis, CA, United States of America; United States Department of Agriculture, Western Human Nutrition Research Center, Davis, CA, United States of America.
Abstract
BACKGROUND: Fructose consumption increases risk factors for cardiometabolic disease. It is assumed that the effects of free sugars on risk factors are less potent because they contain less fructose. We compared the effects of consuming fructose, glucose or their combination, high fructose corn syrup (HFCS), on cardiometabolic risk factors. METHODS: Adults (18-40 years; BMI 18-35 kg/m2) participated in a parallel, double-blinded dietary intervention during which beverages sweetened with aspartame, glucose (25% of energy requirements (ereq)), fructose or HFCS (25% and 17.5% ereq) were consumed for two weeks. Groups were matched for sex, baseline BMI and plasma lipid/lipoprotein concentrations. 24-h serial blood samples were collected at baseline and at the end of intervention. Primary outcomes were 24-h triglyceride AUC, LDL-cholesterol (C), and apolipoprotein (apo)B. Interactions between fructose and glucose were assessed post hoc. FINDINGS: 145 subjects (26.0 ± 5.8 years; body mass index 25.0 ± 3.7 kg/m2) completed the study. As expected, the increase of 24-h triglycerides compared with aspartame was highest during fructose consumption (25%: 6.66 mmol/Lx24h 95% CI [1.90 to 11.63], P = 0.0013 versus aspartame), intermediate during HFCS consumption (25%: 4.68 mmol/Lx24h 95% CI [-0.18 to 9.55], P = 0.066 versus aspartame) and lowest during glucose consumption. In contrast, the increase of LDL-C was highest during HFCS consumption (25%: 0.46 mmol/L 95% CI [0.16 to 0.77], P = 0.0002 versus aspartame) and intermediate during fructose consumption (25%: 0.33 mmol/L 95% CI [0.03 to 0.63], P = 0.023 versus aspartame), as was the increase of apoB (HFCS-25%: 0.108 g/L 95%CI [0.032 to 0.184], P = 0.001; fructose 25%: 0.072 g/L 95%CI [-0.004 to 0.148], P = 0.074 versus aspartame). The post hoc analyses showed significant interactive effects of fructose*glucose on LDL-C and apoB (both P < 0.01), but not on 24-h triglyceride (P = 0.340). CONCLUSION: A significant interaction between fructose and glucose contributed to increases of lipoprotein risk factors when the two monosaccharides were co-ingested as HFCS. Thus, the effects of HFCS on lipoprotein risks factors are not solely mediated by the fructose content and it cannot be assumed that glucose is a benign component of HFCS. Our findings suggest that HFCS may be as harmful as isocaloric amounts of pure fructose and provide further support for the urgency to implement strategies to limit free sugar consumption.
BACKGROUND: Fructose consumption increases risk factors for cardiometabolic disease. It is assumed that the effects of free sugars on risk factors are less potent because they contain less fructose. We compared the effects of consuming fructose, glucose or their combination, high fructose corn syrup (HFCS), on cardiometabolic risk factors. METHODS: Adults (18-40 years; BMI 18-35 kg/m2) participated in a parallel, double-blinded dietary intervention during which beverages sweetened with aspartame, glucose (25% of energy requirements (ereq)), fructose or HFCS (25% and 17.5% ereq) were consumed for two weeks. Groups were matched for sex, baseline BMI and plasma lipid/lipoprotein concentrations. 24-h serial blood samples were collected at baseline and at the end of intervention. Primary outcomes were 24-h triglyceride AUC, LDL-cholesterol (C), and apolipoprotein (apo)B. Interactions between fructose and glucose were assessed post hoc. FINDINGS: 145 subjects (26.0 ± 5.8 years; body mass index 25.0 ± 3.7 kg/m2) completed the study. As expected, the increase of 24-h triglycerides compared with aspartame was highest during fructose consumption (25%: 6.66 mmol/Lx24h 95% CI [1.90 to 11.63], P = 0.0013 versus aspartame), intermediate during HFCS consumption (25%: 4.68 mmol/Lx24h 95% CI [-0.18 to 9.55], P = 0.066 versus aspartame) and lowest during glucose consumption. In contrast, the increase of LDL-C was highest during HFCS consumption (25%: 0.46 mmol/L 95% CI [0.16 to 0.77], P = 0.0002 versus aspartame) and intermediate during fructose consumption (25%: 0.33 mmol/L 95% CI [0.03 to 0.63], P = 0.023 versus aspartame), as was the increase of apoB (HFCS-25%: 0.108 g/L 95%CI [0.032 to 0.184], P = 0.001; fructose 25%: 0.072 g/L 95%CI [-0.004 to 0.148], P = 0.074 versus aspartame). The post hoc analyses showed significant interactive effects of fructose*glucose on LDL-C and apoB (both P < 0.01), but not on 24-h triglyceride (P = 0.340). CONCLUSION: A significant interaction between fructose and glucose contributed to increases of lipoprotein risk factors when the two monosaccharides were co-ingested as HFCS. Thus, the effects of HFCS on lipoprotein risks factors are not solely mediated by the fructose content and it cannot be assumed that glucose is a benign component of HFCS. Our findings suggest that HFCS may be as harmful as isocaloric amounts of pure fructose and provide further support for the urgency to implement strategies to limit free sugar consumption.
Authors: M-R Taskinen; S Söderlund; L H Bogl; A Hakkarainen; N Matikainen; K H Pietiläinen; S Räsänen; N Lundbom; E Björnson; B Eliasson; R M Mancina; S Romeo; N Alméras; G D Pepa; C Vetrani; A Prinster; G Annuzzi; A Rivellese; J-P Després; J Borén Journal: J Intern Med Date: 2017-06-27 Impact factor: 8.989
Authors: Mi-Sung Kim; Sarah A Krawczyk; Ludivine Doridot; Alan J Fowler; Jennifer X Wang; Sunia A Trauger; Hye-Lim Noh; Hee Joon Kang; John K Meissen; Matthew Blatnik; Jason K Kim; Michelle Lai; Mark A Herman Journal: J Clin Invest Date: 2016-09-26 Impact factor: 14.808
Authors: R Bucala; Z Makita; G Vega; S Grundy; T Koschinsky; A Cerami; H Vlassara Journal: Proc Natl Acad Sci U S A Date: 1994-09-27 Impact factor: 11.205
Authors: Desiree M Sigala; Bettina Hieronimus; Valentina Medici; Vivien Lee; Marinelle V Nunez; Andrew A Bremer; Chad L Cox; Candice A Price; Yanet Benyam; Yasser Abdelhafez; John P McGahan; Nancy L Keim; Michael I Goran; Giovanni Pacini; Andrea Tura; Claude B Sirlin; Abhijit J Chaudhari; Peter J Havel; Kimber L Stanhope Journal: Nutrients Date: 2022-04-15 Impact factor: 6.706
Authors: Sabrina Ayoub-Charette; Laura Chiavaroli; Qi Liu; Tauseef Ahmad Khan; Andreea Zurbau; Fei Au-Yeung; Annette Cheung; Amna Ahmed; Danielle Lee; Vivian L Choo; Sonia Blanco Mejia; Russell J de Souza; Thomas Ms Wolever; Lawrence A Leiter; Cyril Wc Kendall; David Ja Jenkins; John L Sievenpiper Journal: J Nutr Date: 2021-08-07 Impact factor: 4.687
Authors: Desiree M Sigala; Adrianne M Widaman; Bettina Hieronimus; Marinelle V Nunez; Vivien Lee; Yanet Benyam; Andrew A Bremer; Valentina Medici; Peter J Havel; Kimber L Stanhope; Nancy L Keim Journal: Nutrients Date: 2020-12-19 Impact factor: 5.717
Authors: Desiree M Sigala; Bettina Hieronimus; Valentina Medici; Vivien Lee; Marinelle V Nunez; Andrew A Bremer; Chad L Cox; Candice A Price; Yanet Benyam; Abhijit J Chaudhari; Yasser Abdelhafez; John P McGahan; Michael I Goran; Claude B Sirlin; Giovanni Pacini; Andrea Tura; Nancy L Keim; Peter J Havel; Kimber L Stanhope Journal: J Clin Endocrinol Metab Date: 2021-10-21 Impact factor: 6.134